Algorithms for early detection of silent liver fibrosis in the primary care setting – a scoping review

References

• Zobair Younossi PG, Golabi P, Paik J, et al. The most recent and in-depth meta-analytic assessment of the global epidemiology of non-alcoholic fatty liver disease (NAFLD). J Hepatolo, Abstract Book. 2022;77:S144–S145. doi: 10.1016/S0168-8278(22)00668-7
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi: 10.1053/j.gastro.2020.01.052
   PubMed Web of Science ®Google Scholar
• Asrani SK, Kouznetsova M, Ogola G, et al. Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004–2013. Gastroenterology. 2018 Sep;155(3):719–729.e4. doi: 10.1053/j.gastro.2018.05.032
   PubMed Web of Science ®Google Scholar
• Chedid MF. Nonalcoholic steatohepatitis: the second leading indication for liver transplantation in the USA. Dig Dis Sci. 2017;62(10):2621–2622. (1573–2568 (Electronic)). doi: 10.1007/s10620-017-4724-6
   PubMed Web of Science ®Google Scholar
• Dam Fialla A, de Muckadell OB S, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012 Jun;47(6):702–709. doi: 10.3109/00365521.2012.661759
   PubMed Web of Science ®Google Scholar
• Idalsoaga F, Kulkarni AV, Mousa OY, et al. Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities. Front Med (Lausanne). 2020;7: (2296–858X (Print)).
   PubMed Web of Science ®Google Scholar
• Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017 Mar;66(3):610–618. doi: 10.1016/j.jhep.2016.11.011
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547–1554. doi: 10.1002/hep.27368
   PubMed Web of Science ®Google Scholar
• Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150(8):1778–1785. (1528–0012 (Electronic)). doi: 10.1053/j.gastro.2016.03.005
   PubMed Web of Science ®Google Scholar
• Sandrin L, Fourquet B, Fau - Hasquenoph J-M, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–1713. (0301–5629 (Print)). doi: 10.1016/j.ultrasmedbio.2003.07.001
   PubMed Web of Science ®Google Scholar
• Ulasoglu C, Enc FY, Kaya E, et al. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J Gastrointestinal and Liver Dis. 2019;28(4):427–431. (1842–1121 (Electronic)). doi: 10.15403/jgld-293
   PubMed Web of Science ®Google Scholar
• Thong VD, Quynh BTH. Correlation of serum transaminase levels with liver fibrosis assessed by transient elastography in Vietnamese patients with nonalcoholic fatty liver disease. Int J Gen Med. 2021;14:1349–1355. doi: 10.2147/IJGM.S309311
   PubMed Web of Science ®Google Scholar
• Allan R, Thoirs K, Fau - Phillips M, et al. Accuracy of ultrasound to identify chronic liver disease. World J Gastroenterol. 2010;16(28):3510. (2219–2840 (Electronic)). doi: 10.3748/wjg.v16.i28.3510
   PubMed Web of Science ®Google Scholar
• Grattagliano I, Ubaldi E, Fau - Napoli L, et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Ann Hepatol. 2013;12(1):70–77. (1665–2681 (Print)). doi: 10.1016/S1665-2681(19)31387-0
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping Reviews (PRISMA-ScR): checklist and explanation. Ann internal med. 2018;169(7):467–473. (1539–3704 (Electronic)). doi: 10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Tavaglione F, Jamialahmadi O, De Vincentis A, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023;21(6):1523–1532.e1. (1542–7714 (Electronic)). doi: 10.1016/j.cgh.2022.03.044
   PubMed Web of Science ®Google Scholar
• Sripongpun P-O, Kim W-O, Mannalithara A, et al. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care. Hepatology. 2023;77(1):256–267. (1527-3350 (Electronic)). doi: 10.1002/hep.32545
   PubMed Web of Science ®Google Scholar
• Yip TC, Ma AJ, Wong VW-S, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther. 2017;46(4):447–456. (1365–2036 (Electronic)). doi: 10.1111/apt.14172
   PubMed Web of Science ®Google Scholar
• Hydes T, Moore M, Stuart B, et al. Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data. BMJ Open. 2021 Feb 11;11(2):e044952. doi: 10.1136/bmjopen-2020-044952
   PubMed Web of Science ®Google Scholar
• Blanes-Vidal V, Lindvig KP, Thiele M, et al. Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care. Sci Rep. 2022 Feb 21;12(1):2914. doi: 10.1038/s41598-022-06998-8
   PubMed Web of Science ®Google Scholar
• McLernon DJ, Donnan PT, Sullivan FM, et al. Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. BMJ Open. 2014;4(6):e004837–e004837. (2044–6055 (Print)). doi: 10.1136/bmjopen-2014-004837
   PubMed Web of Science ®Google Scholar
• Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2567–2576. doi: 10.1016/j.cgh.2021.12.034
   PubMed Web of Science ®Google Scholar
• Åberg F, Luukkonen PK, But A, et al. Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score. J Hepatol. 2022 Aug;77(2):302–311. doi: 10.1016/j.jhep.2022.02.021
   PubMed Web of Science ®Google Scholar
• Coste P, Llop E, Perelló C, et al. Comparison of non-invasive fibrosis scores to predict increased liver stiffness in the general population with unknown liver disease: searching for the primary physician’s best friend. Digestive Liver Dis. 2022;54(9):1209–1214. (1878–3562 (Electronic)). doi: 10.1016/j.dld.2022.03.013
   Web of Science ®Google Scholar
• Younossi ZM, Pham H, Felix S, et al. Identification of high-risk patients with nonalcoholic fatty liver disease using noninvasive tests from primary care and endocrinology real-world practices. Clin Transl Gastroenterol. 2021 Apr 6;12(4):e00340. doi: 10.14309/ctg.0000000000000340
   PubMed Web of Science ®Google Scholar
• Eslam M, Wong GL, Hashem AM, et al. A Sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in Hospital-based and primary care patients. Am J Gastroenterol. 2021;116(5):984–993. (1572–0241 (Electronic)). doi: 10.14309/ajg.0000000000001059
   PubMed Web of Science ®Google Scholar
• Mansour D, Grapes A, Herscovitz M, et al. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep. 2021 Aug;3(4):100293. doi: 10.1016/j.jhepr.2021.100293
   PubMedGoogle Scholar
• Harman DJ, Ryder SD, James MW, et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open. 2015 May 3;5(4):e007516. doi: 10.1136/bmjopen-2014-007516
   PubMed Web of Science ®Google Scholar
• Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019 Aug;71(2):371–378. doi: 10.1016/j.jhep.2019.03.033
   PubMed Web of Science ®Google Scholar
• Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the Enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology. 2018 Apr;154(5):1369–1379. doi: 10.1053/j.gastro.2018.01.005
   PubMed Web of Science ®Google Scholar
• Shaheen AA, Riazi K, Medellin A, et al. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open. 2020;8(2):E370–E376. (2291–0026 (Print)). doi: 10.9778/cmajo.20200009
   PubMedGoogle Scholar
• Bedogni G, Kahn Hs Fau - Bellentani S, Bellentani S, et al. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10(1): (1471–230X (Electronic)). doi: 10.1186/1471-230X-10-98
   PubMedGoogle Scholar
• Zelber-Sagi S, Ratziu V, Fau - Zvibel I, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol. 2012;24(3):262–269. (1473–5687 (Electronic)). doi: 10.1097/MEG.0b013e32834f15dd
   PubMed Web of Science ®Google Scholar
• Wong V-O, Zelber-Sagi S-O, Cusi K, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42(11):2377–2389. doi: 10.1111/liv.15404
   PubMed Web of Science ®Google Scholar
• Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: review of management for primary care providers. Mayo Clin Proc. 2022;97(9):1700–1716. doi: 10.1016/j.mayocp.2022.04.005
   PubMed Web of Science ®Google Scholar
• Kumar A, Pant S, Narang S. Significance of alanine aminotransferase testing in diagnosis of acute and chronic HBV infection. Asian Pac J Cancer Prev. 2009;10(6):1171–1172.
   PubMedGoogle Scholar
• Nowicki MJ, Poley JR. The hereditary hyperbilirubinaemias. Baillière’s Clinical Gastroenterology. 1998;12(2):355–367. (0950–3528 (Print)). doi: 10.1016/S0950-3528(98)90139-7
   PubMedGoogle Scholar
• Roulot D, Costes JL, Buyck J-F, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011 Jul;60(7):977–984. doi: 10.1136/gut.2010.221382
   PubMed Web of Science ®Google Scholar
• Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity. World J Hepatol. 2021;13(11):1584–1610. (1948–5182 (Print)). doi: 10.4254/wjh.v13.i11.1584
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Tsochatzis E, Boursier J. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021 Sep;75(3):659–689. doi: 10.1016/j.jhep.2021.05.025
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. LID. [doi] FAU - Rinella, Mary E. (1527–3350 (Electronic)) doi: 10.1097/HEP.0000000000000323
   Google Scholar
• Ciardullo S-O, Ronchetti C, Muraca E, et al. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. J Endocrinol Invest. 2020;43(7):1019–1026. (1720–8386 (Electronic)). doi: 10.1007/s40618-020-01188-7
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Paik JM, Biswas R, et al. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5(11):1833–1847. (2471–254X (Electronic)). doi: 10.1002/hep4.1765
   PubMed Web of Science ®Google Scholar